Development of Gene Therapy Targeting Cancer Glucose Metabolism

Development of Gene Therapy Targeting Cancer Glucose Metabolism

With the continuous development of transgenic technology and gene editing technology, gene therapy has ushered in a new era of cancer treatment. Gene therapy has become a hot spot in cancer research due to its advantages of high specificity, strong targeting, and few side effects. At present, the main methods of gene therapy include suicide gene therapy, gene silencing therapy, tumor suppressor gene therapy, immune system therapy, and anti-angiogenic gene therapy.

With the study of the function of abnormal glucose metabolism in cancer in the process of tumorigenesis and development, the expression of glucose metabolism-related genes directly or indirectly affects tumor proliferation, metastasis, immunosuppression, and angiogenesis. Therefore, gene therapy drugs designed to target abnormal glucose metabolism genes have been considered promising strategies for the treatment of cancer. CD BioGlyco is a professional cancer glucose metabolism researcher and can provide customers with gene therapy strategy development services for abnormal glucose metabolism in cancer cells.

What We Do for Gene Delivery System of Cancer Glucose Metabolism Gene Therapy

  • Selection and preparation of abnormal glucose metabolism genes
    Through the MOPCGM platform, we can help customers to screen out the potential genes of interest that can be applied to gene therapy from the heterogeneous and flexible reprogramming process of cancer glucose metabolism.
  • Vector construction for cancer glucose metabolism gene therapy
    The development of gene therapy delivery systems is inseparable from the construction of vectors. An ideal gene therapy vector needs to overcome extracellular barriers and efficiently transfer the therapeutic gene into target cells. The gene therapy vector construction services we can provide are as follows:
Adenovirus
Adenovirus is double-stranded DNA virus with a maximum titer of 1012 PFU/ml, capable of infecting differentiated and undifferentiated cells, expressing exogenous fragments less than 5 kb, and has high immunogenicity.
Lentivirus
Lentivirus is RNA virus with a maximum titer of 109 TU/ml, capable of infecting differentiated and undifferentiated cells, expressing exogenous fragments less than 4 kb, and has low immunogenicity.
Adeno-associated virus
Adeno-associated virus is single-stranded DNA viruses with a maximum titer of 1012-13 v.g/ml, capable of infecting cells that do not divide as well, expressing exogenous fragments less than 2.8 kb, and has minimal immunogenicity.
Exosomes
Exosomes regulate the mRNA of target cells by capturing mRNA secreted by somatic cells and converting them into proteins. Exosomes have low immunogenicity and can increase the circulation time of the carried drugs in the body, and have potential as gene therapy carriers.

What We Do for Gene Editing of Cancer Glucose Metabolism Gene Therapy

CRISPR/Cas9 technology has a powerful editing operation function, which can accurately screen the entire genome in a short time. At CD BioGlyco, we are able to use CRISPR/Cas9 technology to repair or knock out genes with abnormal glucose metabolism to develop new cancer treatment strategies.

What We Do for RNA interference of Cancer Glucose Metabolism Gene Therapy

Abnormal glucose metabolism is closely related to the high expression of certain genes. RNA interference technology can affect the replication of specific genes and lead to the lack of corresponding proteins, thereby further inhibiting tumor progression. We are able to provide gene therapy strategy development services for RNA interference targeting genes with abnormal glucose metabolism.

What We Do for Safety and Toxicology Analysis of Gene Therapy

  • We are able to provide toxicity analysis services for cancer glucose metabolism gene therapy systems.
  • We are able to provide off-target toxicity analysis services for cancer glucose metabolism gene therapy strategies.
  • We can provide safety assessment services for gene therapy strategies.

Our Advantages

  • Based on the MOPCGM platform, we are able to provide professional gene therapy development services targeting abnormal genes of glucose metabolism.
  • Based on the functional analysis services of exosomes in cancer glucose metabolism, we are able to provide gene therapy development services using exosomes as carriers.

CD BioGlyco can provide gene therapy strategy development services targeting genes with abnormal glucose metabolism in cancer. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.

This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.